|
Status |
Public on Nov 01, 2017 |
Title |
The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by array
|
Summary |
Double Hit Lymphoma (DHL) were treated with the BRD4 inhibitor 100 nM CPI203 for 6h We used microarrays to uncover the mechanisms underlying CPI203 activity in Double Hit Lymphoma (DHL)
|
|
|
Overall design |
Global RNA expression was done in three DHL cell lines and two DHL patients treated in vitro with CPI203 for 6h
|
|
|
Contributor(s) |
Valero JG, Arenys AE, Roué G |
Citation(s) |
29353886 |
|
Submission date |
May 15, 2017 |
Last update date |
Jul 25, 2021 |
Contact name |
Juan Garcia Valero |
E-mail(s) |
GARCIA32@clinic.ub.es
|
Organization name |
IDIBAPS
|
Department |
Oncology and haematology
|
Lab |
Physiopathology and molecular bases in hematology
|
Street address |
Rosselló, 153
|
City |
Barcelona |
State/province |
Barcelona |
ZIP/Postal code |
08036 |
Country |
Spain |
|
|
Platforms (1) |
GPL13667 |
[HG-U219] Affymetrix Human Genome U219 Array |
|
Samples (10)
|
|
Relations |
BioProject |
PRJNA386866 |